rsna final 2.1 web version - ge | the digital industrial ... execution & rigor growth through...

RSNA Investor Meeting November 29, 2007

GE Healthcare

WelcomeDan Janki

“This document contains "forward-looking statements" - that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties which could adversely or positively affect our future results include: the behavior of financial markets, including fluctuations in interest rates and commodity prices; strategic actions, including dispositions; future integration of acquired businesses; future financial performance of major industries which we serve, including, without limitation, the air and rail transportation, energy generation, media, real estate and healthcare industries; unanticipated loss development in our insurance businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive and regulatory nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

2 / GE Healthcare RSNA Investor Meeting

November 29, 2007

Today’s agenda

10:30 – 10:45 Welcome and Introduction

- Dan Janki- Joe Hogan

10:45 – 12:45 GE Healthcare Booth Tourand Lunch

1:00 – 3:00 GE Healthcare – Winning Today, Winning Tomorrow

3:00 – 3:30 Q&A


GE Healthcare: Overview

Joe HoganPresident & CEO, GE Healthcare


November 29, 2007

RSNA 2007 – GE drives ‘Early Health’

Innovation - Tech Pavilion-Healthcare 5+ years out

One GE

Integrated displays

Larger footprint

100+ products

Customer engagement - Open designfor easier navigation and crowd control

Integrated CampaignPre/during/post RSNA. Print, web, events, buses, PR

What’s new

CT LightSpeed HD, LightSpeed VCT XT,

MI Motion Free PET, Infinia Hawkeye 4,

MR Signa Vibrant, Signa HDx,

XR Senographe Essential, Volume RAD, Definium 5000,

U/S LOGIQ 9 Care area series/4D probe

HCIT Centricity PACS, Radiology, RIS-IC, PACS-IW, RIS/PACS,Radiology-IW, Radiology Outreach, Cardiology Info System, RIS/PACS EMEA, Dynamic Imaging

Link to future with Tech Pavilion

Workflow to products to Early Health

Introduction to Dynamic Imaging

Re-brand booth, integrate messaging


GE Healthcare: Overview


“This document contains "forward-looking statements" - that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties which could adversely or positively affect our future results include: the behavior of financial markets, including fluctuations in interest rates and commodity prices; strategic actions, including dispositions; future integration of acquired businesses; future financial performance of major industries which we serve, including, without limitation, the air and rail transportation, energy generation, media, real estate and healthcare industries; unanticipated loss development in our insurance businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive and regulatory nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

Key messages todayGE Healthcare: Tough 2007… stronger 2008Anticipate OEC on track 1Q 2008 DRA 2008 better comparisons

Strong global growthSolid strategy in existing marketsExplosive growth in emerging markets

Exciting pipelineInnovation & segmentation

Strong services growthMigration to higher value offerings

Healthcare trendsRegulatory reimbursement pressureDemographics/public policy Data & information driving healthcare decisions

‘Age of Early Health’ GE at the forefront

+2%

GE Healthcare 2007 overview

Great business, tough 2007, positioned for stronger 2008

~$17B

~$3.1B

Strengths

• Strong global growth

• Services growth & execution

• Strength in IT & Life Sciences

• Strong pipeline of new products

Headwinds

• DRA US impact

• OEC Consent Decree

• Japan slowdown

OP 18%

-2%

Revenue35%

65%

~(14)%

~12%

Revenue

Population snapshot: US, EU5 & Japan

Healthcare environment

2004 2009E

Aging

2007E 2015E

Burden of disease

Healthcare spending

Diabetes

Oncology

Cardiology

Obesity

��13%

Total spend ($B)

Near term pressures

Reimbursement

• Payment systems designed to contain costs

• US Deficit Reduction Act (DRA) & Japan cap on spend

Regulatory

• Europe & US increased regulatory vigilance1960

-

1972

1972-

1975

HMO

Act

1975-

1977

1977-

1979

Carter

Initiatives

1979-

1982

1982-

1987

DRG

1987-

1990

1990-

1995

1995-

2000

Managed

Care

2000-

2007E

2007E-

2010E

DRA

Annual % Increase

Demand for IT solutions• US: Healthcare in political spotlight• UK IT and technology investment• Europe: EU white paper focus on prevention/IT

7.6%

3.5%

6.8%

4.1%

6.1%

4.9%

7.0% 7.3%

5.6%

7.5%

6.4%

~265

Population over 50 years MM

~260~300

Great market, strong future

2.2

1.4

.42.15

.78

US healthcare spending resiliency

US W EU Japan China ROW

PrevalenceMM

��8%

% GDP 15.8 8.8 7.9 5.4 6.1

250


November 29, 2007

13% CAGR

2000 2004 2007E

GE Healthcare 7 year growth trend

How we grow

� Industry-leading technology

�Global, product & services reach

�World-class execution & rigor

�Growth through disease focus

�Efficacy & efficiency focus

Positioned for continued growth

Medical Diagnostics

Diagnostic Imaging

Clinical Systems

Healthcare IT

Life Sciences

$7

~$17

$13

(Revenue $ in billions)

Three complementary, technology platforms

Creating new opportunities, positioned for growth

Information Technology

Broad-based Diagnostics

Life Sciences

Medical Diagnostics

Electronic medicalrecords

Protein & cell sciences

Diagnostic Imaging

Discovery tools

Integrated admin/clinical

ClinicalSystems

Picture Archiving Systems (PACS)

Clinical: tissue biomarkers

50% Revenues & Employees overseas

GE Healthcare: A global business

16,900 / 34%

8,600 / 18%

22,100 / 45%USA

Europe & MEA

Asia

Americas1,500 / 3%

Building a strong global position


CAGR%

Europe

Japan

China

AGM/LA

EE/MEA 18

15

9

2

18

2000 2007E

$3

~$8

13%CAGR

Our Vision: Healthcare Re-imagined

We are transforming healthcare by helping predict,diagnose, treat andmonitor disease earlier to improve quality of life

Goal: $400B+ diagnostic spending shift over the next decade

Monitor12%

Monitor10%

Treat60%

Treat70%

Diagnose19%

Predict5%

Predict9%

Diagnose15%

Future

Today

Global healthcare spend = $4T

10%shift


November 29, 2007


November 29, 2007

GE well positioned

Reduces hospital stays

Drives better clinical outcomes

Reduces mortality

Diagnostic shift: Major developments 2007

…that are shaping public policy worldwide

• Cost of heart disease = 1% GDP/Year• Cost of mental disorders = 3-4% of GDP/Year

Actions:• More investment in prevention• Drive quality outcomes + IT

EU Health Whitepaper 2008-13Presidential Health Plan Elements

MD Anderson - Ultrasound effective for less common breast cancer staging

Science - DNA test to identify early heart attack risk

ACRIN study - CTC matches colonoscopy for colon cancer screening

US Nat’l Cancer Institute - death rates from cancer � 2.1% a year since 2002

64 Slice CT identify patients, without invasive caths, needing heart surgery

New data reinforcing value of Dx…

Trends play to GE offerings

• Transparency• Digitization IT

All Candidates agree:• Quality outcomes• Disease diagnosis & prevention

US cancer deathsdown 2.1%

Age of early health is here

• Prostate cancer continues to fall: screening, PSA

• Breast cancer rates decreased 3.5%: first drop in 20 yrs

• Colorectal cancer 5yr survival: 10% late stage; 90% early detection

“The decline in cancer has little to do with improvements in late stage treatment...but more to do with screening, earlier detection and treatment."

Prof. Gordon McVie, European Institute of Oncology, Milan

Prostate cancer deaths

0

20

40

60

1975 2003

Prostate

Per 100K m

ales

Deaths down 4.1%0

15

30

45

Colorectal cancer deaths

Male

Female

1975 2003

Per 100K pop Deaths down 4.9%

Deaths down 4.5%

Breast cancer deaths

0

15

30

45

1975 2003

Breast

Deaths down 3.5%Per 100K females

Innovation + clinical data = new markets

Visipaque: first choice for renal-compromised patients

GE upside

64 slice CT = cardiac cath in heart disease detection

Digital mammo better in dense breast tissue

1st yr med students with hand carried U/S better than cardiologists

Great technology and clinical data drive growth

Recent research on GE technology

Premium pricing 35%+ CAGR

20%+ increase digital sales: 9 month backlog

GE Compact U/S +52% �� 06/07

Global CT growth

Hospitals & powerful IT reduce central line cath infections GE/Intermountain

GE Business How US savings

HCIT 34% EMR adoption in US

DI CT, MR, PET, SPECT in-patient imaging

$5B annually/Medicare

Clinical Systems $1.2Bannually/Medicare

$32B annually

In-patient ultrasoundLunar for Osteoporosis

GE helps drive healthcare savings

Front end diagnostics & IT saving ~$40B/year

GEHC platforms driving early health

Diagnostics driving healthcare value

Organs

Molecules

Targetedtherapies

One sizefits all

Rx Dxtandem

Tissues

Dx enabling Rx stratification

HealthValue

High

Low

Broad-basedDiagnostics

InformationTechnology

Life Sciences

Wholebody

Theage ofEarlyHealth

Data driven healthcare


November 29, 2007

Today’s speakers

Mark Vachon, President & CEO, Diagnostic Imaging

Reinaldo Garcia, President & CEO, International

John Chiminski, President & CEO, Medical Diagnostics

Omar Ishrak, President & CEO, Clinical Systems

Peter Ehrenheim, President & CEO, Life Sciences

Vishal Wanchoo, President & CEO, GE Healthcare IT


GE Healthcare Diagnostic Imaging: Leading positions, great fundamentals

Mark VachonPresident & CEO, Diagnostic Imaging


November 29, 2007

6%CAGR

Diagnostic Imaging: Leading positions, great fundamentals

$6

2003 2007E

~$8

Key messages

• Global leadership

#1 CT #1 MR

#1 PET #1 X-Ray

• ~$30B Market… demographics + technology = sustained growth

• Diagnostics value proven by HC economics

• Strong global growth… US market challenging

• Robust product development continues

• Services accelerating customer value



November 29, 2007

Powerful weapons… leading fight against disease

Imaging is central to confronting the "Big 6"

Cardiacdisease

Alzheimer’sdisease

Coloncancer

Breastcancer

~$400+B

~$100+B

~$14+B

~$15+B

Diabetes

~$131+B

Lung cancer

~$5+B

� Find disease earlier

� Leverage- Biology- Chemistry- Physics- Engineering- Genomics- Informatics

Technology evolution advancing care

Image quality drives new applications & usage

Dramatic increases in imaging accuracy

Cardiac CT 1979 Breast MR 1998 PET (FDG) 1995

Lightspeed VCT NOW

Breast MR NOW

PET/CTNOW


November 29, 2007

High growth procedures

Heart �50%

CT Colonography �20%

Brain �17%

Breast �50%

Cancer �37%

Brain �43%

� Rapid MI growth - PET and NM adoption

� MR - adoption for Breast, Stroke, Abdomen

� CT - Cardiology, Neurology, Oncology

� X-Ray - digital transformation

2006

CAGR

12%7%

8%

CTMR

MI

XR47%

Digital

Global procedures - attractive growth

2003

696

2009E

~915(Procedures MMs)

815

PET

VCT

MR

Robust product development

FastLab

Tomosynthesis

• Integrated coil & biopsy table• 50% procedure growth

• Digital revolution• Common platform• Multiple configurations

• Tomo, mobile, & stereo• Unique solutions• Scaleable platform

• Improved lesion detectability• Tracks tumor motion - ++ therapy

• 5 Beat cardiac, 83% lower dose• Stroke assessment with 24% lower dose, 2X coverage

VCT XT

Dedicatedbreast MR

Definium

Motion-free PET

New products driving $3B of growth over 3-years

• 50% more FDG, efficient multi-tracer platform


November 29, 2007

MR

DXR

MICT

9 sites to 4

7 sites to 4: LCC dominate

8 sites to 5: Dual capabilities

Goldseal 75% in LCC

Market and cost alignmentSupply Chain Engineering

40% ↓↓↓↓ in sites �� 69% of labor in LCC

2006 2010E

High costcountry

Low cost

• Customer intimacy

• Products in country for country strategy

• Global platforms + productivity

Productivity funding investments

65%

35%

~50%

~50%


November 29, 2007

U.S. environmentGrowth strategy

• Adjusted Cost; Commercial focus

• Drive technology; Customer solutions

• Advocacy

Continued challenges

• Continued pressures through 1H 2008

• Advocacy becomes critical

US DI market ($B) - NEMA

04 05 06 07E 08EMkt V% 11% 4% 7% (15%) ~0%

~$5.8~$5.5

~$6.2

~$5.3 ~$5.3

In just 5 areas imaging saves Medicare ~$5B annually

Disease US Incidence Savings/year

400K ER visits/year

Savings per $1 spent

Stroke 700K $468MM$2.64

7MM patients/year

$1.15

250K/year1MM hospital days

$2.96

$1.63

Diagnostic Imaging = better care + economics

$112MMER chest pain

Heart disease $163MM

Appendicitis $111MM

Inpatientcare

Imaging saves 3.6MM hospital days annually

CMS savings >$4.3B/Year

$4.00 saved per $1 spent

Global DI - geographic portfolio

Geographic diversity Double digit growth in 5 of 8 regions

� AGM: region growing 2-3x GDP

� Japan: positive reimbursement trends

� China: market recovering, growth in CT

� Europe: west funding east

� Latin America: healthy economies

� US: DRA & regulatory pressure

� Canada: MR++, PET++, Radio-pharma ++

CAGR

Americas

2000 2007E

$5

~$8

MEA

China

Japan

AGM 10%

0%

5%

20%

5%

~5%CAGR

Europe 10%


EE 15%


November 29, 2007

All P&L’s: Services driving higher value

Break/FixMaintenance

ContractServices

Upgrades andSoftware

Performance Solutions

Comprehensive Services

Technical Training and Education

• Full customer productivity engagements

• Total outsourcing

• Customer renewals/clinical IT

• Multi-year customized agreements, focus on digital and remote

• Demand service: labor and parts

• Performance management

Broad service capability

$3.7

2005

~$5.7

2007E2003

14%CAGR

B/L $4.4 $6.5 ~$7.4

$4.7



November 29, 2007

Expanding Services solution portfolio

Optimizing assets Optimizing processes Optimizing people

~$2.5

10E07E

~$3.0

Market size: ~$25B GE share: <10%

• Comprehensive asset management

• Capital planning

• Asset tracking/RFID

~$0.1

10E07E

~$0.4


• ED/OR throughput and efficiency

• Hospital of the Future

• Patient flow/RFID

~$0.2

10E07E

~$0.4


• Leadership education… NCHL JV

• Lean Six Sigma

• Patient safety/quality

(Revenue $B)


November 29, 2007

Diagnostic Imaging

Leading positions, great fundamentals

� ~$30B Market…demographics + technology = sustained growth

� Diagnostics value proven by HC economics

� Strong global growth… US market challenging

� Robust product development continues

� Services accelerating customer value


GE Healthcare: Driving growth in International

Reinaldo GarciaPresident & CEO, GEHC International

International: Continued strong growthInternational footprint

Key messages

• Long term double digit growth

• Diverse growth strategies

- Developed: share gain, segmentation

- Emerging: market creation, localization

- Focus on fast developing economies

• #1 or 2 in most geographies

• Win by scale, expertise, FAST deployment

DI ServicesClinicalSystems

MDx LS IT

Robust strategy driving growth


CAGR%

Europe

Japan

China

AGM/LA

EE/MEA 18

15

9

2

18

2000 2007E

$3

~$8

13%CAGR

~8-11%

Germany

� Public restructuring continues

� New private opportunities

UK

� Focus on stroke centers

� New trend: Outpatient centers

� 2008: GPO opportunity

France

� Imaging strong: Market � in 2008 new push for CT, MR & PET

� Next: Tackling Alzheimer’s

Spain

� PET centers: Next big focus

� Overseas expansion priority

Growth trends in developed mkts… Europe

European Union

� Healthcare controlled by member states

� Benchmarking drives standards

Different countries: different needs

Collective interest in enhancing healthcare

HC spend % of GDP0% 6% 12%

Ireland

Austria

Finland

Spain

Sweden

Italy

United Kingdom

Denmark

Greece

Belgium

Portugal

Germany

France

Netherlands


November 29, 2007

Segmentfocus

14%

18%AAGR

GE growth in developed markets

Sales ($B)

2007E

$1.2

~$3.9

2000

Western Europe

2006 2007E

$0.6

Winning in Germany

Growth strategy

� Experienced & specialized sales force

� Segmentation by country and market

�Marketing aligned with national spend

� Country management: One GEHC

$0.5

Growth strategy

� Segmentation: private practices, academics, hospital chains

� Local capability… from headquarters to Germany

2007 Share gains

CT: � 10ptsU/S: � 12ptsMR: � 6ptsMammo: � 5pts

Sales ($B)

2 pts = 4X

Company to country sell

Growth in emerging marketsHuge healthcare opportunities for GE

• Big populations: limited healthcare access

• Undeveloped healthcare infrastructure

• Financing needs… access to funding

Emerging growth drivers

• Oil and commodities boom

• Healthcare infrastructure projects

• Privatization trends… entrepreneurs

• Healthcare insurance

Developed Developing

8-11%

3-6%

Healthcare spend % of GDP

~$40B

Emerging markets technology segment growth

~$11B

2007E 2020E

GE sales ~$2.9B~$10-12B

GE advantage: fund, plan, build entire HC Infrastructure Fast


November 29, 2007

12%CAGR

Explosive growth in emerging markets(GE Sales $B)

28%CAGR

+15% +10% +9% +13% +9%

13%CAGR

12%CAGR

20%CAGR

RegionMkt Growth

~$5B by 2010

� Company to country� Government loans & local manufacturing� Funding growth… GE & third party funding� Growth through Enterprise approach� Localization of capabilities… regional focus

MEACAT

~$1.0

~$0.5

2007E 2010E

Latin America

~$0.7

~$0.5

2007E 2010E

China

~$1.0

~$0.7

2007E 2010E

EE & CIS

~$0.6

~$0.4

2007E 2010E

AGM

~$1.2

~$0.8

2007E 2010E

“Go Big” opportunities


November 29, 2007

Ministry of Health challenges

Population seeking better healthcareGovernment understand “health is wealth”

Broad portfolio of equipmentGlobal benchmark capacity

On going opportunities

• Morocco… Maternal-Infant Care, Oncology, Cardiology

• Pakistan… Hospital upgrades

• Egypt… Emergency, ICU’s and OR

• Ukraine… Breast cancer screening

• Georgia… “100 new hospitals”

• Abu Dhabi… Breast cancer management

• Romania… Hospital upgrades

• Bulgaria… Cardiology program

“Go Big” company to country

• Inefficient infrastructure• Workforce capacity and skill• Child and mother mortality• Infectious diseases + Oncology and CVD

Seeing GE as credible partner

• Capture curiosity• Develop joint roadmap• Execute recommendation

Deal funnel

220

450

~850 ($MM)

2006

68106

Orders

~180

($MM)

2007E2005 2006 2007E2005

12-18 mths opportunity

$130-175MM

‘’Go Big’’ Funding growth through financing solutions

Capital Markets Corporate

HealthcareFinancialServices

Orders financed

Developed Developing Emerging

G

E

O

R

G

I

A

CMC regional deploymentHFS regional deployment25 effective FTE’s130 effective FTE’s

Funding Growth… GE & third party funding

Creative solutions serving market needs

Exporting Importing

10-15 Russia

5-10 China

~20 China

~10 Latin America

15-20 EE, SEA

10-20 Africa

~10 Africa

~30 China, Vietnam

20-40 MEA

USA

China

Israel

Saudi

Korea

Spain

Finland

Austria

Hungary

• Country to country loans to promote exports

• Very favorable terms

• GE well positioned with manufacturing in lending countries

AnnualLoan $MM

Buy

Equipment

Government backed loans & SKD’s

2008E2006

~$1.1B

$0.9B


November 29, 2007

Big GE win:$21MM

‘’Go Big’’ growth through Enterprise approach

GE Delivers

• Advisory

• Hospital planning

• Procurement

• Installation and maintenance

• Clinical and Mgmt education

• Financing

• Consultancy

Innovative, FAST, Implementation

Case Study: Turkey

Who: Universal Hospitals Group

Size: 43 Hospitals and Clinics

What the customer wanted: Immediate national/international expansion

Challenge: Outfit 4 hospitals in Turkey, one in Albania within 2 months

5.3%CAGR

2%CAGR

‘’Go Big’’ localization of capabilities

GDP

Africa

Middle East

Turkey/CA

Russia/CIS

2007E 2010E

~$4.6T

~$5.6T

2007E 2010E

~1.7B~1.8B

Population

� GDP & population growth 2-3X OECD� Primary & infant care gvt initiatives� New private sector = investment funds� Hospital creation/rejuvenation� Shortage of physicians + all HCPs

� Enhanced focus on region� Increased coverage� Better market knowledge & presence� Inside knowledge, access, networks� GE sales ~$1.2B by 2010

Market size $2.8B… growing 15-20%

Strong fundamentals… tremendous growth opportunities

Driving growth in International

� Diverse growth strategies

- Developed: share gain, segmentation

- Emerging: market expansion, localization

- Focus on fast developing economies

� #1 or 2 in most geographies

� Winning by scale, expertise, FAST deployment

Long term double digit growth


GE Healthcare: Medical Diagnostics driving Early Health today & tomorrow

John Chiminksi President & CEO, Medical Diagnostics

7%CAGR

Medical Diagnostics driving Early Health today and tomorrow

World’s largest, strongest imaging agent business

#1 Nuclear #1 Optical

#1 X-Ray #2 MR

Key messages

• Growth via Life Cycle Mgmt & new products

• World-class R&D and clinical trial capability

• Strong synergies with GE…+ global

• Globalization expanding market opportunities

$1.5

2003 2007E

~$1.9


High margin business positioned for growth

Breadth across modalities & disease areas

Cardiology

Oncology

Neurology

Urology

Optical Imaging

TargetedSPECT

PETMR SPECTX-Ray/CT

5% 10% 2% 29% 13% 5% Segment Growth(2003-2007 CAGR)

Positioned to capture high-growth segments

Anatomy Function Perfusion Viability Metabolism

03 07E

03 07E

03 07E

03 07E

03 07E

45%

23%

8%

(1%)

4%

Life cycle mgmt delivers organic growth

� Dementia with Lewy Bodies� Expand target audiences –

Geriatricians, psychiatrists

� Expand GEHC footprint� New patient populations –

Metabolic syndrome, Women

� CT colonography with Oral� Novel packaging

� New clinical data in cardiac/CT� New target audiences – Peds, ER

202

~470

Launched 2000 First agent to identify Parkinson’s Disease

Launched 1996Myocardial perfusion

� Cardiac� Target outpatient imaging centers

Launched 1993 Non-ionic MRI

361 ~416

246~331

175 ~168

9

~38

Launched 1982Global Gold standard

Launched 1996ONLY Iso-Osmolar media

Product Description 5 year CAGRRevenues in $MM

Growth actionsclinical plans

29% CAGR since 2002

55% CAGR since 2002

Proof: Clinical validation drives growth

NEPHRIC

ACC/AHA Guidelines

Recover

COURT VICC

MetaAnalysis

Parkinson’s Syndrome

indication

• 1st choice for renal-compromised patients

• Clinical differentiation drives premium price

• ACC/AHA guidelines… A+ recommendation

• One GEHC offering with VCT

• Dementia indication doubles patient population

• Expanded customer base: psychiatrists, psycho-geriatricians

• Securing reimbursements in key countries

MACE / C

T CIN

Neurology

sales force

155211

293

370

449~473

~557

9

15

2428

~38

~46

2002 2004

5

Clinical utility -DLB

2006 2008E2002 2004 2006 2008E

Clinical data + new indications = increased revenues

Clinical utility -PS

Dementia


November 29, 2007

$120MM*

Enabler ofnovel tracers

$150MM*

Annual revenue potential ~$1B

Driving one new product per year

New productDisease diagnosisand detection

SonazoidUltrasound

Cancer lesions in the LiverOncology

AdreViewSPECT

Neuroblastoma. Heart Failure Oncology, Cardiology

2007: Japan

2008: Global

2009: N. Am

2008: EU and US

Anticipated launch

HexvixOptical

Bladder Cancer detection Oncology

2006: Europe2008+: RoW, US

FastLab/SteriPETPET

Manufacture of PET cancer agents Oncology, Cardiology, Neurology

DatSCANSPECT

Parkinson’s and DementiaNeurology

2010: EU/USPiBPET

Amyloid in Alzheimer’s Neurology

�

�

1 new product year

“One GE”

* Peak year sales

$570MM*

$200MM*

$50MM*

Partner with Clinical Systems

Chemistry + Engineering

Partner with Clinical Systems

Global Imaging NetworkPharma collaborations

Integrated Development Electronic Capture

Regulatory Interactions


November 29, 2007

Est. incremental revenues ($MM)*

Diagnosing heart disease…first major advance in SPECT for 50 years

Driving growth through integrated offerings

5X productivity

2X patient volume

50% less false negatives

Motion free… 27 cameras

+=

+

Efficiency �� Accuracy ��

UltraFast cardiac

Myoview

Advanced applications

~$35

~$70

~$100

2008E 2009E 2010E

*UF Cardiac+ Myoview

Capitalizing on regional growth… $90+MM

($MM)

12%

+4%Marketgrowth(2007-2008)

Europe

• 2-3x market growth

• Distribution + “Go Direct”

• Drive key brands in developing markets

• Drive ionic to non-ionic

Strategy

Market growing fast… GE growing faster

2007E 2008E

30%

2007E 2008E

+8%

Latin Am

20%

2007E 2008E

+12%

MEA

20%

2007E 2008E

+14%

Asia


November 29, 2007

High margin business positioned for growth

� World-class R&D and clinical trial capability

� Growth via Life Cycle Management and new products

� Strong synergies with GE imaging capabilities + global

� Globalization expanding market opportunities

Medical Diagnostics driving Early Health today and tomorrow


GE Healthcare Clinical Systems Business built on new market creation

Omar IshrakPresident & CEO, Clinical Systems


November 29, 2007

11%CAGR

$2.9

2003 2007E

~$4.4


Key messages

• Segmentation… proven success model

• Dynamic environment… growth strategies in place

• Less dependent on reimbursement

• Sustained margin expansion & strong growth

Leading point-of-care technology in hospitals, offices and home

Ultrasound Cardiology

Monitoring Bone Densitometry

Anesthesia Maternal-Infant Care

Winning through innovation and market segmentation

$16B Point of Care

Market

Patient-CentricVision

CustomerFocus

DistributionProduct

Alignment

10%

$5.6

Services

10%8%15%

$3.2$2.9$4.2

SpecialtiesMonitoringUltrasound

Mkt ($B)

GE Rev V%

• Share gains in every business

• Innovation driving double digit revenue

• 90% of market not dependent on reimbursement

Markets & performance

Net Promoter Score +11

pts

Segmentation… proven success model

Right product, right customer drive growth

Consistent share gain↑↑↑↑ 3 pts/yr

Attractive imaging

modality in DRA environment

Value productsCompact product linesHigh-end Platforms

Radiology

$1.5

1%

7%

Mkt ($B)

Mkt V

GE CAGR(04-10)

Women’sHealth

$1.1

3%

15%

Cardiology

$1.1

4%

11%

Compact

$0.5

22%

54%

� Launch annual breakthroughs

� Sustained cost productivity

� Focused global distribution

15%CAGR

~ ~

Revenue($B)

1.6

0.7

~1.8

~2.7

Radiology

Women’s Health

Cardiology

Compact

Service

2010E2000 2006 2007E

Driving image quality excellence

Creating new markets & users

Accelerating adoption

Strategy

TECHNOLOGY MIGRATION

• Vivid

• Voluson

• Logiq

• Radiology

• Women’s Health

• Cardiology

• New Apps

• Perform. Color

• Access B&W

• Rural China

Proof: Ultrasound…growth accelerating

Hyper-market segmentation

Infrastructure build drives demand

New $1BMarket

+5ptsMarket share

(05-07)

Critical Care

$1.3B

4%

11%

07 $B Mkt

07 Mkt V

GE CAGR(04-10)

Peri-Op

$0.7

3%

10%

Neonatal

$0.3

8%

12%

Wireless

$0.6

7%

11%

� Care area excellence

� Clinical information logistics

�Market creation

Strategy

Ubiquitous MonitoringIntegrated SystemsDepartmental

Solutions

Growth via

care area excellence

Infrastructure drivingworkflow solutions

Technology enablesmass deployment

10% CAGR

~ ~2004

0.8

2007E

~1.1

~1.4

2000

0.3

2010E

WIRELESS & MINIATURIZATION

Revenue($B)

Proof: Monitoring solutions… a global leader

Hyper-market segmentation

Clinical Systems growth strategies

Care deliveryEconomics/payors

Costs Reimb.

GlobalizationDemographics

Enabling customers to adapt in a dynamic environment

• Multiple departments

• High acuity

HOSPITAL• Disease management

• Wellness

HOMECLINIC• Multiple specialists

• Episode prevention

CS

CS

CS

CS

CSCS CS

Acuity

PRESENT

FUTURE

Uti

liza

tio

n

CS

CS

CS

CS

CS

CS

CS

CS

Low

InnovationInnovation UbiquitousproductsUbiquitousproducts ConvergenceConvergence Customer

reachCustomer reach

$100 every 3 years

04 07E 10E

ASP ↑↑↑↑ 5% Cost ↓↓↓↓13% CM ↑↑↑↑ 4 pts

Ubiquitous monitoring: Patient data module (PDM)

PDM/Ubiquitous Revenue($MM)

~$80~$140

~$300

Growth strategy: Innovation

Innovation in action: Panda warmer

Advancing care delivery

$116

~$200

~$305

CAGR ↑↑↑↑ 14% CM ↑↑↑↑ 8 pts

• Steady heat to the newborn • Caregiver cool and comfortable• Hands-free alarm silencer may reduce infection

Fueling sustained growth

MIC Revenue($MM)

• Miniaturized full-function monitor• Supports efficient patient workflow• Ensures data continuity / consistency

Winning with technology & scale…2007 product launches

07E 08E 10E

Other

Anesthesiology

GE CAGR 82%

(2004 –2007E)Emergency medicine

& critical care

Specialized imaging

• Rheumatology

• Breast surgery

• Specialized & dedicated products & distribution

• New innovation with breakthroughs

Growth in compact U/S sales

$100

$147

$50$44 $46

$116

$174

$54

$171

2004 2005 2006 2007E

GE targeting new ultrasound users

$530MM compact market

CAGR 36%

Compact driving procedure efficiency…cost ↓↓↓↓, quality ↑↑↑↑, safety ↑↑↑↑

Strong revenue growth

Growth strategy: Ubiquitous products

Compact ultrasound revenue($MM)

GE #152%V

~$265

~$60

~$201

GE Healthca

re

Sonosite

07E 10E03

10% CAGR

07E 10E

~403

~545Anesthesia revenue($MM)

AisysCarestation

04

304

Anesthesia

Monitoring

Clinical Information

Incremental $100MM RevenueUltrasound Patient

Monitoring

Anesthesia

Operating Room

Ultrasound

Monitoring147

Revenue($MM) 247

102

• Build on strong anesthesia products and customer relationships

• Extend clinical sales offerings into Labor & Delivery and Emergency Department

• Leverage customer intimacy/observation

• Streamline clinical workflow & reduce medical errors

• Broad array of technologies to deliver customer need

Growth Strategy: Convergence

Harnessing the breadth of Clinical Systems

Identify unique customer need:Technology convergence

Footprint to migrate to new areas:Commercial convergence

Convergence drives incremental growth

8x Increase (06 – 08E)

7 New Products(06 - 07)

GE breadth & technology driving advantage

•Need in > 2500 counties in rural co-operations

•Local practice patterns demand U/S and ECG

• Dedicated local engineers

• Focused sales channel

• New products at every China Medical Equipment Fair (CMEF)

ECG

U/S

GE upgrades local practice needs

Local commitment & understanding

Today Future

World’s largest show 2X/yr

CMEF

• Broad range of products

• Launch new products every 6 months

• Creating the foundation of healthcare in China

584

07E 08E06

2,246 units

~4,800

~3,140Rural Health Units Sold

Growth Strategy: Customer reach

GE offerings: ‘Must haves’ for all rural clinics

Winning in Rural Health with “In China for China” strategy


November 29, 2007

Clinical Systems: Business built on market creation

� Segmentation… proven success model

� Dynamic environment… growth strategies in place

� Less dependent on reimbursement

� Sustained margin expansion & strong growth

Breadth & depth driving double-digit growth


GE Healthcare: Life Sciences winning in core and future markets

Peter EhrenheimPresident & CEO, Life Sciences


November 29, 2007

10%CAGR

Life Sciences winning in core and future markets

$1.1

2005 2007E

~$1.3

Key messages

• Sales of $1.3B in a $20B, growing market

• Channel to pharma industry

• Great position in Biopharma tools

• Good profit leverage

• Bridging biological discovery & clinical practice

(Revenue $ in billions) Global Leader in Life Science tools

Biopharmaceutical manufacturing

Protein purification

Cellular imaging

Antibody binding analysis

Drug screening technologies


November 29, 2007

Growth• $20B+ segment

• Fragmented market

• Strong franchise in Bioprocess and Protein sciences

Pharma offerings• Preferred supplier to many Biopharma / Pharma companies

• Channel to pharmaprofit pools…

Bridging research & clinical

• Visibility of early trends

• IP useful in imaging (e.g. C11)

• Technologies for diagnostics

Life Sciences: What’s in it for GEHC?

Bench to Bedside


November 29, 2007

• Cell culture• Filtration• Disposables

Strong Biotechnologies business

GE Products designed into manufacturing processes

GE “benefits from”biopharma growth

GE Healthcare:Inside biopharmaceuticals

GE products/processes used in production of over 90% of all FDA approved biopharmaceuticals

• Enabling biopharmaceutical production

• GE products in all steps of the manufacturing process

GE expanding to new applications:

• Double digit market growth• Market leader in protein purification• 350+ products in development Bio/Pharma

Strong growth in core market:

Antibody-based, vaccines driving market growth

~74~82

~98

07E 08E 10E

$B

Global sales of biotherapeutics


November 29, 2007

AXP systemProteomics BioArchive

PET isotopesCytodexCells

BiomarkerIdentification

TrackingAdmin.StorageQCManipulation/ Expansion

Separation/ SelectionCell Source

Genetic Susceptibility Create diagnostic

Driving NEW molecular diagnostics and imaging

Molecular markers identify high risk populations for cancer imaging

Driving NEW cell therapies: i.e. heart disease

Adult stem cells are isolated and processed to treat heart disease

Early tumour detectionTissue Imaging

Life Sciences integrates other GEHC platforms

Diagnostic Screening

Proteomics Disease/Pathology Staging

Genomics

Molecular Cellular In Vivo

Wealth of biological data

Life Sciences’presence in biosupplier markets…

…generates a wealth of biological

data & disease understanding

Opportunity for GE Healthcare IT

Translating data into diagnostic value requires strong data handling & processing capabilities


November 29, 2007

� Sales of $1.3B in a $20B, growing fragmented market

� Channel to pharmaceutical industry

� Great position in biopharmaceutical tools

� Good profit leverage

� Bridging biological discovery & clinical practice

Great business positioned for Strong 2008

Life Sciences winning in core and future markets


GE Healthcare: Effective IT integration key to the future of healthcare

Vishal WanchooPresident, Healthcare Information Technology

22%CAGR

Healthcare IT vehicle for healthcare transformation

Providing clinical and financial IT solutionsimproving HC costs and careRadiology Info Systems PACS EMR systems Revenue cycle

Key messagesHealthcare IT positioned to win across key segments:

• $20B market growing at 8-10%

• Imaging: Opportunity for more market penetration

- Dynamic Imaging acquisition tech win

• Physician office: Demand for EMR, decision support

• Hospital: Intermountain “go-live” with co-developed software

• Data aggregation digital pathology: Big mkts for GE

$0.8

2003 2007E

~$1.8

Next page

Positioned for double digit growth


20% penetration EMR

$3B market8% growth

15% EMR penetration

$800MM market 12% growth

Healthcare IT growth strategy

Imaging

Adoption of IT: Why now? GE strategy Market opportunity

� Increase offerings IB

�Dynamic Imaging to medium/small hospitals

�Expand to cardio & pathology

Hospital

� Intermountain Healthcare partnership

�Use EMR to � clinical outcomes via decision support

�Build on product breadth & reputation to win

Physician office

�Enhanced applications to customer base to drive EMR

�Utilize EMR data for secondary markets

50% penetration$2.5B market 8% growth

Health systems under huge pressure

Radiology first to digitize…tremendous benefits

Digitization spreading

to other departments

EMR adoption is exploding

EMR adoption drives data aggregation market

$1.8B globalmarket

… and well-positioned as market moves horizontally and to med/small hospitals

GEHC good position in fragmented market

Position of strength to address high-growth global market segments

� Dynamic #1 in customer ranking

� Quick Install Cycle critical

� =Dynamic’s Web-based technology

GE’s distribution & brand recognition

DigitalPathology

To adjacent space

Med/SmallHospitals

Large Hospitals

Radiology Cardiology

RIS/PACS technology

Imaging… access everywhere

+

6%

23%

32%

11%

7%

13%

8%

GE Healthcare

Carestream

Others

Fuji

Agfa

McKesson

Siem

ens

% Market

80%adoptionin 8 years

Digital Pathology… $1B global market

Expected Digital adoption rates based upon PACS

• � diagnostic accuracy & productivity

• � turn-around time for consulting

• Expand access to pathology sub-specialists

• Enable integration to EHR10E 12E 14E 16E

GE developed scanner technology

Dynamic web-based platform

GEHC IT capabilities

+ Clinical collaboration for viewing/analytics

80%

50%

20%10%

• High volume factory-like flow

• Demand increasing… 7% AGR

• Shortage of Pathologists

Labor intensive process

Diagnosis of disease through examination of tissues/cells

GE driving transition from ‘slides to digital’

~16% CAGR~14% CAGR

Market accelerating

Government incentives: IT Win• Pay for Performance (P4P)

• Reimbursement reforms

Stark relaxation•�� expense for physician adoption

• Expand throughout physician office

07E

~1.5

08E

~1.7

10E

~2.2

Meeting current customer needs

• User interface & workflow

• Financial/clinical integration

• Hosting offerings for smaller practices

Physician office market strong

($ in billions)

Creating “data market” opportunity• Quality reporting & reimbursement

• $7B Pharma market… safety and efficacy

Multitude of physician needs: plays to GE expertise


07E

~0.4

08E

~0.5

10E

~0.6

35%* �� in diagnosis

50%* �� in diagnosis for atypical symptoms

OutcomesMeasurable MeaningfulScalable

• Portal to improve patient care… persistency & compliance

• Patients recruited from Physician Offices and NBCU

• Data from GEHC EMR + Portal to provide outcomes

*3 month preliminary results

Partnering with Pharma to improve therapy

$100MM opportunity over 3-5 years

iVillage Total HealthHealthology

Patient ChannelPatients and CaregiversHealthcareProfessionals

Yourcondition.com

CentricityEHR

Gastroesophageal Reflux Disorder

Example

Data aggregation

market

Transformationalreleases

1st Go Live

Automation

Evolution

Transformation

Financial

Departmental applications

Clinical

Today1980s 1990s

Decision support

GE & Intermountain partnership… key to transformational technology

Clinicalcollaboration

Independentsoftwarevendors

GEHC IT growing 20%+ over next 5 years!

New England Journal of Medicine

Hours of antibiotic therapy

Days in hospital

Costs for hospital

With IT

103

10

$26K

None

330

17

$44K

�70%�40%�40%

Market forces accelerating adoption

GE + Intermountain

Driving better patient outcomes

Hospital market transforming

Evidence-based care

Advanced Decision Support

‘10

‘08

‘07

‘09

Go Live at


November 29, 2007

Effective IT integration key to the future of healthcare

Next page

Healthcare IT positioned to win across key segments:

� $20B market growing at 8-10%

� Imaging: Opportunity for more market penetration

- Dynamic Imaging acquisition tech win

� Physician office: Demand for EMR, decision support

� Hospital: Intermountain “go-live” with co-developed software

� Data aggregation digital pathology: Big markets for GE

Positioned for double-digit growth


GE Healthcare: Summary


GE Healthcare 2008 summary

Great business well positioned

2008 growth drivers~5-7%

~10%

• OEC shipments resumed

• Strong global growth

• Exciting 2008 product pipeline

• Strong services backlog

• Quality and regulatory processes

• Efficiency and productivity

OP

2008E

OP% 19%

$0.8

Revenue


Thank you

rsna final 2.1 web version - ge | the digital industrial ... execution & rigor growth through...

Documents